Dr. Mahapatra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8200 Dodge St
Omaha, NE 68114Phone+1 402-955-8919Fax+1 402-955-3262- Is this information wrong?
Summary
- My research background in the effects of heat shock on protein biosynthesis (undergraduate), the rescue of neuronal apoptosis in neurodegenerative conditions (PhD), and the mitigation of neuronal and systemic inflammation using amyloidogenic peptides (fellowship) have bestowed upon me not only a strong foundation in the molecular exploration of neuropathobiology, but also a focused interest in ameliorating afflictions of the central nervous system. As a pediatric intensivist with burgeoning expertise in neurocritical care working in an area with a particularly high incidence of pediatric brain tumors, I am now concentrating my strengths in molecular neurobiology and translational science to investigate pediatric medulloblastomas (MB), the most common malignant brain tumor of childhood. Divided into 4 subgroups, current cure rates reach as high as 95% for the WNT subgroup and small molecule targeted therapies have reached clinical trials for the SHH subgroup. Patients falling into subgroup 3 suffer the worst prognoses due to: 1) high-risk cytogenetic events such as loss of chromosome 17p and c-Myc amplification, 2) high rates of metastases at diagnosis, and 3) high relapse rates fueled by age-based restrictions on current therapeutic interventions. A dearth of pre-clinical models and poor insight into pathophysiology further characterize group 3 tumors as the worst amongst MB patients. To address this knowledge and survival gap, my lab is investigating genetic drivers of tumorigenesis specifically related to chromosome 17p to elucidate pathophysiology that can be targeted in high risk tumors. In the current proposal, I plan to elucidate how iron homeostasis and glutathione metabolism enable cancer cells to mitigate ferroptosis thus driving aggressiveness. My hope is to enable us to exploit this mechanistic knowledge to generate safe, well-tolerated, targeted therapeutic approaches that improve survival and quality of life for group 3 MB patients.
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Critical Care Medicine, 2012 - 2015
- Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 2009 - 2012
- Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2009, MD, Alpha Omega Alpha
- School of Graduate and Post-doctoral Studies at Rosalind Franklin UniversityPhD, Biochemistry & Molecular Biology, 2003 - 2007
- Knox CollegeBachelor's, Molecular Biology, Magnum Cum Laude, 1997 - 2001
Certifications & Licensure
- NE State Medical License 2015 - 2024
- CA State Medical License 2010 - 2016
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Critical Care Medicine
Awards, Honors, & Recognition
- UNeMed New Invention Contributor: Identification of Nortriptyline as a Potential Therapeutic for Group 3 Medulloblastoma UNeMed Corporation, UNMC, 2022
- Loan Repayment Award Recipient NIH/NCI, 2022
- Active Membership Society for Pediatric Research, 2022
- Join now to see all
Publications & Presentations
PubMed
- A National Meeting for the American Federation for Medical Research: Decades in the Making.Mahapatra, S.> ;Journal of Investigative Medicine. 2024 Mar 1
- 1 citationsWNT-activated, MYC-amplified medulloblastoma displaying intratumoural heterogeneity.Green, S., Hoover, T., Doss, D., Davidow, K., Walter, A., Cottrell, C., Mahapatra, S.> ;Neuropathology and Applied Neurobiology. 2024 Feb 1
- 14 citationsMicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.Parvez Khan, Jawed Akhtar Siddiqui, Prakash G Kshirsagar, Ramakanth Chirravuri Venkata, Shailendra Kumar Maurya, Tamara Mirzapoiazova, Naveenkumar Perumal, Sanjib Chau...> ;Molecular Cancer. 2023 Jan 4
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- MiR-1253 Potentiates Vincristine Response in Pediatric MedulloblastomaKanchan RK, Atri P, Venkata RC, Batra SK, Mahapatra S, 19th International Symposium on Pediatric Neuro-Oncology, Karuizawa, Nagano, Japan, 12/2020
- Retrospective Analysis of Feeding Practices and Outcomes in Bronchiolitis Patients on NIPPVMahapatra S, Lukowski J, Ramos V, Lenihan A, Nemec N, Society for Critical Care Medicine, Orange County, FL, 2/17/2020
- MiR-1253 Potentiates Vincristine Response in Pediatric MedulloblastomaLukowski JD , Kanchan RK, Perumal N, Atri P, Venkata RC, Nasser MW, Batra SK, Mahapatra S., Annual Nebraska and Iowa Physicians of Indian Origin Meeting, Omaha, NE, 8/7/2019
- Join now to see all
Lectures
- AAP COVID-19 Pediatric Emergency Readiness & Response ECHO Session 5: COVID-19 TestingOmaha, NE - 5/14/2020
- E-cigarette/Vaping Associated Lung Injury (EVALI)Nebraska State Education Association, Lincoln, NE - 2/23/2020
- Medulloblastoma: Past Misconceptions, Present Challenge, and Future PromiseUniversity of Toledo Department of Neuroscience - 2/18/2020
- Join now to see all
Other
- Well Child ChecklistMahapatra, S, AgileMD
http://www.agilemd.com
4/18/2014 - Health care: A right that must be shared by allMahapatra, S., Maharaj, S., Pharos
The Chicago Medical School at Rosalind Franklin University - 12/1/2008 - Identification of critical residues within the conserved and specificity patches of nerve growth factor leading to survival of differentiationMahapatra, S, ProQuest Dissertations and Theses., Doctoral Dissertation
North Chicago, IL - 7/1/2007
Press Mentions
- The Challenge of Treating Childhood Brain CancersAugust 25th, 2023
Grant Support
- Elucidating mitochondrial iron transporter-mediated ferroptosis in group 3 medulloblastomaBuffet Cancer Center2023–2024
- Targeting B7-H3 (CD276) mitigates tumor aggressiveness in group 3 medulloblastomaEdna Ittner Foundation2022–2023
- MiR-1253 potentiates cisplatin response in group 3 medulloblastoma through ferroptosisNICHD/NIH2021–2023
- Chemosensitization of non-SHH/WNT medulloblastoma is regulated by miR-1253Team Jack Brain Tumor Foundation2020–2022
- NFIB’s Role in Medulloblastoma Stem Cell RenewalNebraska Department of Health & Human Services2020–2021
- Elucidating the oncogenic role of NFIB in group 3 MBNebraska Department of Health & Human Services2020–2021
- Exploring the oncogenic properties of NFIB in group 3 MBAmerican Cancer Society/Buffet Cancer Center2020–2021
- Chemosensitization of group 3 MB is regulated by miR-1253Edna Ittner Foundation # 010287802019–2020
- Identification of tumor suppressor genes on chromosome 17p13.3 in non-SHH/WNT MBPediatric Cancer Research Center2017–2020
- Exploration of Anti-tumorigenic Effects of Chol-miR-1253 Polyplexes in MedulloblastomaNIH/NIGMS2018–2019
- Elucidation of miR-1253 as a putative tumor suppressor gene in non-SHH/WNT MBFrank & Pamela Buffet Cancer Center2018–2019
- Identification of Tumor Suppressor Genes on Chromosome 17p13.3 for the Generation of a non-SHH/WNT Subgroup Murine Model of MedulloblastomaCheryl Lozier Pediatric Grant2017–2018
- Elucidation of miR-1253 as a putative tumor suppressor gene in non-SHH/WNT MBEdna Ittner Foundation # 010287802017–2018
Research History
- Site DirectorPROSpect: PRone and OScillation PEdiatric Clinical Trial is a multi-center randomized clinical trial examining if prone vs. supine and oscillator vs. CMV are superior modes of managing severe PARDS.2019 - 2025
- Primary investigatorOver 60% of patients with medulloblastoma harbor mutations on chromosome 17p13.3. We are currently exploring the properties of tumor suppressor genes on this locus with the intent of elucidating molecular mechanisms of carcinogenesis and generating targeted small molecular inhibitors.2015 - Present
- Co-investigatorIn medulloblastoma, miR-1253 is significantly downregulated. In this proposal, by complexing with PLL(30)-PEG(5K), we hope to increase the potency of cholesterol-modified miR-1253 against medulloblastoma after i.v. administration.2018 - 2019
- Site DirectorPediatric Acute Respiratory Distress Syndrome Incidence and Epidemiology (PARDIE) Study: The major goal of this multi-center point prevalence study was to understand the implications of the new PALICC definitions of Pediatric ARDS (PARDS) on the incidence and epidemiology of PARDS.2016 - 2017
- Junior Investigator (Fellowship)In this study of amyloid-forming proteins, we found that the amyloidogenic hexapeptide, amylin, improved illness severity, reduced mortality, attenuated the cytokine cascade, and preserved lung barrier function in a murine mouse model via a sustained increase in IL-10 levels.2013 - 2015
- Junior Investigator (Ph.D.)Through this study, we generated an NGF mutant protein (SS-1) capable of discriminatory intracellular signaling effectively abrogating neuritogenesis. We, thus, generated a pro-survival agent capable of rescuing cell death in Alzheimer’s disease.2003 - 2009
- Junior Investigator (Undergraduate Honors)In a 3-hr time-course study of heat-shock, we discovered that mRNAs encoding secretory proteins are selectively destabilized and degraded within the first 30 mins on the endoplasmic reticulum; the release of signal recognition particles (SRPs) from the ER is also inhibited.1998 - 2001
Professional Memberships
- Member
- Member
- Member
- Member
- Society for Neuro-Oncology - SNOMember
- Society for Pediatric ResearchMember
- Sigma XiMember
Other Languages
- Hindi
Hospital Affiliations
- Children's NebraskaOmaha, Nebraska
- CHI Health Creighton University Medical CenterOmaha, Nebraska
External Links
- UNMC Profilehttps://www.unmc.edu/pediatrics/divisions/critical-care/faculty/mahapatra.html
- PubMed Bibliographyhttps://www.ncbi.nlm.nih.gov/labs/bibliography/1-U2a9HLZTFA4/bibliography/public/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: